Abstract:Objective To investigate host IL28B and viral genotype differences in responses to antiviral therapy efficiency in chronic HCV patients.Methods The study had 120 patients,who were able to complete the full course of combination therapy with pegylated interferon-α and ribavirin.Ninety-two patients were followed for 24 weeks after the cessation of treatment.The treatment efficiency was evaluated with end-of-treatment response(ETR) and sustained virological response(SVR).A logistic regression model was applied to analyze the association of treatment efficacy with host IL28B and viral genotypes.Results The higher rates of ETR(P= 0.001 4) and SVR(P= 0.000 7) were observed in HCV genotype 1b infected patients with IL28B genotype CC than the rates in HCV genotype 1b infected patients with IL28B genotype N-CC.However,there was no significant difference in treatment efficiency between HCV genotype N-1b infected patients with IL28B genotype CC and HCV genotype N-1b infected patients with IL28B genotype N-CC.In the participants with IL28B genotype N-CC,the HCV genotype N-1b infected patients had higher rates of ETR(P=0.035 0) and SVR(P=0.022 2) than HCV genotype 1b infected patients did.However,there was no significant difference in treatment efficiency between IL28B genotype CC patients infected with HCV genotype 1b infection and IL28B genotype CC patients infected with N-1b.Conclusions HCV and host IL28B genotypes were associated with outcomes of patients treated with pegylated interferon-α and ribavirin.The determination of host IL28B and HCV genotypes could provide a reliable basis for individual therapy and predicting treatment efficacy.

Host Genotyping and Direct-Acting Antiviral Agents: a New Era of Individualized Treatment Strategy for Hepatitis C

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Mechanism of resistance to direct-acting antivirals in hepatitis C treatment and management

HCV genotyping and host genotyping: what role will they play in the antiviral treatment

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Clinical practice of direct-acting antiviral agents for chronic HCV infection

Research of HCV variants resistant to direct-acting antiviral agents

Key tasks in the era of direct-acting antiviral for hepatitis C in China

Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C

[Selection of Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection].

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

[Chronic Hepatitis C: Achievement, Challenge and Strategy to Eliminate As a Public Health Threat].

The Burden of Chronic Hepatitis C in China from 2004 to 2050: an Individual‐Based Modeling Study

Host IL28B and Viral Genotype Differences in Responses to Antiviral Therapy Efficacy in Chronic Hepatitis C

Updated treatment protocol for direct-acting antiviral agents for hepatitis C

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China

Recent Advance in Antiviral Drugs for Hepatitis C.

Personalized care approaches to hepatitis C therapy: recent advances and future directions

Clinical timing and benefit of antiviral treatment for hepatitis C